Report Detail

Pharma & Healthcare Global Efavirenz Market Growth 2019-2024

  • RnM2772467
  • |
  • 15 January, 2019
  • |
  • Global
  • |
  • 135 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals.

According to this study, over the next five years the Efavirenz market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Efavirenz business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Efavirenz market by product type, application, key manufacturers and key regions and countries.

This study considers the Efavirenz value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2024 in section 11.7.
Single Efavirenz
Two-drug combination
Three-drug combination
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2024 in section 11.8.
Adults
Children

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol-Myers Squibb
Teva
Mylan
Aurobindo Pharma
Cipla
Macleods Pharmaceuticals
Hetero
Strides Pharma
Gilead Sciences

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Efavirenz consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2024.
To understand the structure of Efavirenz market by identifying its various subsegments.
Focuses on the key global Efavirenz manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Efavirenz with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Efavirenz submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.


Table of Contents

    2018-2023 Global Efavirenz Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Efavirenz Consumption 2013-2023
        • 2.1.2 Efavirenz Consumption CAGR by Region
      • 2.2 Efavirenz Segment by Type
        • 2.2.1 Single Efavirenz
        • 2.2.2 Two-drug combination
        • 2.2.3 Three-drug combination
      • 2.3 Efavirenz Consumption by Type
        • 2.3.1 Global Efavirenz Consumption Market Share by Type (2013-2018)
        • 2.3.2 Global Efavirenz Revenue and Market Share by Type (2013-2018)
        • 2.3.3 Global Efavirenz Sale Price by Type (2013-2018)
      • 2.4 Efavirenz Segment by Application
        • 2.4.1 Adults
        • 2.4.2 Children
      • 2.5 Efavirenz Consumption by Application
        • 2.5.1 Global Efavirenz Consumption Market Share by Application (2013-2018)
        • 2.5.2 Global Efavirenz Value and Market Share by Application (2013-2018)
        • 2.5.3 Global Efavirenz Sale Price by Application (2013-2018)

      3 Global Efavirenz by Players

      • 3.1 Global Efavirenz Sales Market Share by Players
        • 3.1.1 Global Efavirenz Sales by Players (2016-2018)
        • 3.1.2 Global Efavirenz Sales Market Share by Players (2016-2018)
      • 3.2 Global Efavirenz Revenue Market Share by Players
        • 3.2.1 Global Efavirenz Revenue by Players (2016-2018)
        • 3.2.2 Global Efavirenz Revenue Market Share by Players (2016-2018)
      • 3.3 Global Efavirenz Sale Price by Players
      • 3.4 Global Efavirenz Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Efavirenz Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Efavirenz Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Efavirenz by Regions

      • 4.1 Efavirenz by Regions
        • 4.1.1 Global Efavirenz Consumption by Regions
        • 4.1.2 Global Efavirenz Value by Regions
      • 4.2 Americas Efavirenz Consumption Growth
      • 4.3 APAC Efavirenz Consumption Growth
      • 4.4 Europe Efavirenz Consumption Growth
      • 4.5 Middle East & Africa Efavirenz Consumption Growth

      5 Americas

      • 5.1 Americas Efavirenz Consumption by Countries
        • 5.1.1 Americas Efavirenz Consumption by Countries (2013-2018)
        • 5.1.2 Americas Efavirenz Value by Countries (2013-2018)
      • 5.2 Americas Efavirenz Consumption by Type
      • 5.3 Americas Efavirenz Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Efavirenz Consumption by Countries
        • 6.1.1 APAC Efavirenz Consumption by Countries (2013-2018)
        • 6.1.2 APAC Efavirenz Value by Countries (2013-2018)
      • 6.2 APAC Efavirenz Consumption by Type
      • 6.3 APAC Efavirenz Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Efavirenz by Countries
        • 7.1.1 Europe Efavirenz Consumption by Countries (2013-2018)
        • 7.1.2 Europe Efavirenz Value by Countries (2013-2018)
      • 7.2 Europe Efavirenz Consumption by Type
      • 7.3 Europe Efavirenz Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Efavirenz by Countries
        • 8.1.1 Middle East & Africa Efavirenz Consumption by Countries (2013-2018)
        • 8.1.2 Middle East & Africa Efavirenz Value by Countries (2013-2018)
      • 8.2 Middle East & Africa Efavirenz Consumption by Type
      • 8.3 Middle East & Africa Efavirenz Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.2 Efavirenz Distributors
      • 10.3 Efavirenz Customer

      11 Global Efavirenz Market Forecast

      • 11.1 Global Efavirenz Consumption Forecast (2018-2023)
      • 11.2 Global Efavirenz Forecast by Regions
        • 11.2.1 Global Efavirenz Forecast by Regions (2018-2023)
        • 11.2.2 Global Efavirenz Value Forecast by Regions (2018-2023)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Efavirenz Forecast by Type
      • 11.8 Global Efavirenz Forecast by Application

      12 Key Players Analysis

      • 12.1 Bristol-Myers Squibb
        • 12.1.1 Company Details
        • 12.1.2 Efavirenz Product Offered
        • 12.1.3 Bristol-Myers Squibb Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.1.4 Main Business Overview
        • 12.1.5 Bristol-Myers Squibb News
      • 12.2 Teva
        • 12.2.1 Company Details
        • 12.2.2 Efavirenz Product Offered
        • 12.2.3 Teva Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.2.4 Main Business Overview
        • 12.2.5 Teva News
      • 12.3 Mylan
        • 12.3.1 Company Details
        • 12.3.2 Efavirenz Product Offered
        • 12.3.3 Mylan Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.3.4 Main Business Overview
        • 12.3.5 Mylan News
      • 12.4 Aurobindo Pharma
        • 12.4.1 Company Details
        • 12.4.2 Efavirenz Product Offered
        • 12.4.3 Aurobindo Pharma Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.4.4 Main Business Overview
        • 12.4.5 Aurobindo Pharma News
      • 12.5 Cipla
        • 12.5.1 Company Details
        • 12.5.2 Efavirenz Product Offered
        • 12.5.3 Cipla Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.5.4 Main Business Overview
        • 12.5.5 Cipla News
      • 12.6 Macleods Pharmaceuticals
        • 12.6.1 Company Details
        • 12.6.2 Efavirenz Product Offered
        • 12.6.3 Macleods Pharmaceuticals Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.6.4 Main Business Overview
        • 12.6.5 Macleods Pharmaceuticals News
      • 12.7 Hetero
        • 12.7.1 Company Details
        • 12.7.2 Efavirenz Product Offered
        • 12.7.3 Hetero Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.7.4 Main Business Overview
        • 12.7.5 Hetero News
      • 12.8 Strides Pharma
        • 12.8.1 Company Details
        • 12.8.2 Efavirenz Product Offered
        • 12.8.3 Strides Pharma Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.8.4 Main Business Overview
        • 12.8.5 Strides Pharma News
      • 12.9 Gilead Sciences
        • 12.9.1 Company Details
        • 12.9.2 Efavirenz Product Offered
        • 12.9.3 Gilead Sciences Efavirenz Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.9.4 Main Business Overview
        • 12.9.5 Gilead Sciences News

      13 Research Findings and Conclusion

      Summary:
      Get latest Market Research Reports on Efavirenz . Industry analysis & Market Report on Efavirenz is a syndicated market report, published as Global Efavirenz Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Efavirenz market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,660.00
      $5,490.00
      $7,320.00
      2,829.18
      4,243.77
      5,658.36
      3,407.46
      5,111.19
      6,814.92
      558,845.40
      838,268.10
      1,117,690.80
      308,904.00
      463,356.00
      617,808.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report